Company description

Adaptimmune is a clinical-stage biopharmaceutical company that specializes in developing immunotherapies for cancer treatment. Founded in 2008 and headquartered in Philadelphia, Pennsylvania, Adaptimmune has a clear vision to use its unique T-cell receptor (TCR) platform to bring novel and highly potent immunotherapies to patients who are in need. The company is listed on the NASDAQ stock exchange with the ticker symbol ADAP. Adaptimmune's main focus is on developing therapies that can stimulate the immune system to recognize and destroy cancer cells, including solid tumors. With a robust pipeline of therapies in various stages of development, Adaptimmune is dedicated to making a significant impact on the lives of cancer patients worldwide. The company's innovative approach has been recognized with multiple partnerships and collaborations with leading pharmaceutical companies. Adaptimmune is a leader in the field of immunotherapy and is committed to advancing the science and technology of TCR-based therapies to benefit patients in dire need of effective cancer treatments.